Free tool
FAERS Monitor: Zelboraf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202429 or its brand name (Zelboraf, Vemurafenib). Reports on generic versions are filed under their own applications.
Reports
11,990
Serious
8,963
75% of reports
Hospitalization
3,403
Death reported
2,076
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash1,554
- death1,065
- arthralgia1,043
- fatigue1,039
- off label use875
- diarrhoea828
- nausea812
- disease progression768
- pyrexia744
- alopecia563
- decreased appetite534
- vomiting475
- photosensitivity reaction415
- pruritus390
- sunburn373
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 167 |
| 2012 | 1,408 |
| 2013 | 1,462 |
| 2014 | 849 |
| 2015 | 691 |
| 2016 | 2,670 |
| 2017 | 799 |
| 2018 | 842 |
| 2019 | 668 |
| 2020 | 579 |
| 2021 | 453 |
| 2022 | 375 |
| 2023 | 241 |
| 2024 | 467 |
| 2025 | 199 |
| 2026 | 119 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,169 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sunburnSignal | 373 | 92.3 | 83.3 | 31,932 |
| photosensitivity reactionSignal | 415 | 45.2 | 41.1 | 17,458 |
| disease progressionSignal | 768 | 11.5 | 10.7 | 7,311 |
| rashSignal | 1,554 | 6.3 | 6.0 | 7,003 |
| alopeciaSignal | 563 | 5.0 | 4.6 | 1,831 |
| arthralgiaSignal | 1,043 | 4.4 | 4.2 | 2,794 |
| decreased appetiteSignal | 534 | 4.0 | 3.7 | 1,229 |
| pyrexiaSignal | 744 | 3.8 | 3.5 | 1,539 |
| fatigueSignal | 1,039 | 2.3 | 2.2 | 828 |
| diarrhoeaSignal | 828 | 2.3 | 2.1 | 592 |
| deathSignal | 1,065 | 2.2 | 2.0 | 698 |
| nausea | 812 | 1.8 | 1.7 | 299 |
| pruritus | 390 | 1.8 | 1.6 | 135 |
| vomiting | 475 | 1.8 | 1.6 | 163 |
| off label use | 875 | 1.8 | 1.6 | 295 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.